<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJRA</journal-id><journal-title-group><journal-title>Open Journal of Rheumatology and Autoimmune Diseases</journal-title></journal-title-group><issn pub-type="epub">2163-9914</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojra.2021.112009</article-id><article-id pub-id-type="publisher-id">OJRA-109194</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Secondary Hypertrophic Osteoarthropathy or Pierre-Marie Syndrome Bamberger: Clinical Case and Literature Review
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kaba</surname><given-names>Condé</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Carlos</surname><given-names>Othon Guelngar</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Awada</surname><given-names>Mohamed</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Igué</surname><given-names>Kadidjatou</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Douna</surname><given-names>Granga Daouya</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mamadou</surname><given-names>Ciré Barry</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mamadou</surname><given-names>Hady Diallo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Karinka</surname><given-names>Diawara</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Konaté</surname><given-names>Mamady</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Touré</surname><given-names>Moriba</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fodé</surname><given-names>Abass Cissé</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Department of Pediatric, Mother and child Hospital, Ndjamena, Chad</addr-line></aff><aff id="aff4"><addr-line>Department of Pediatric, Academic Hospital, University of Conakry, Conakry, Guinea</addr-line></aff><aff id="aff1"><addr-line>Department of Rheumatology, Academic Hospital, University of Conakry, Conakry, Guinea</addr-line></aff><aff id="aff2"><addr-line>Department of Neurology, Academic Hospital, University of Conakry, Conakry, Guinea</addr-line></aff><pub-date pub-type="epub"><day>22</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>73</fpage><lpage>78</lpage><history><date date-type="received"><day>8,</day>	<month>December</month>	<year>2020</year></date><date date-type="rev-recd"><day>17,</day>	<month>May</month>	<year>2021</year>	</date><date date-type="accepted"><day>20,</day>	<month>May</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Secondary hypertrophic osteoarthropathy, or Pierre-Marie Bamberger syndrome, is characterized by the association of digital clubbing, polyarthritis and periostitis affecting the long bones. Most commonly it is a paraneoplastic syndrome associated with lung cancer in 80% of cases. We report the case of a 49-year-old female patient who is actively smoking, one pack per day for 20 years. Seen in consultation for pain and swelling of the hands, elbows, knees, ankles, and feet evolving for about 5 months, associated with a poorly differentiated pulmonary adenocarcinoma. On history, she told us about a weight loss of about 8 kg, no fever, no cough, no family history of inflammatory rheumatism or cancer. Bilateral digital clubbing was noted. The diagnosis was based on imaging and histology. Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and chemo-radiotherapy was started.
 
</p></abstract><kwd-group><kwd>Hypertrophic Osteoarthropathy</kwd><kwd> Pulmonary Adenocarcinoma</kwd><kwd> Guinea</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Hypertrophic osteoarthropathy (HOA), also called Pierre Marie Bamberger syndrome, was described at the end of the 19th century [<xref ref-type="bibr" rid="scirp.109194-ref1">1</xref>]. It is characterized by a combination of clinical findings of severe disabling arthralgia and arthritis, digital clubbing, and periostosis of tubular bones, with or without synovial effusion [<xref ref-type="bibr" rid="scirp.109194-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.109194-ref3">3</xref>]. HOA can occur as a primary familial autosomal dominant condition called pachydermoperiostosis or secondary to other diseases in (95% to 97% of cases) [<xref ref-type="bibr" rid="scirp.109194-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.109194-ref4">4</xref>]. The secondary forms are due to a wide range of diseases, most frequently by paraneoplastic syndromes which are associated with lung cancer in 80% of cases [<xref ref-type="bibr" rid="scirp.109194-ref5">5</xref>]. The pathophysiology of these two syndromes seems poorly understood, but there is vasodilation in the phalanges with transudate to the interstitium. Palmar angiograms confirm the increase in size and number of digital capillaries. The responsible for this vasodilation would be a humoral substance normally inhibited by the pulmonary capillaries, and therefore, present in the right-left shunts [<xref ref-type="bibr" rid="scirp.109194-ref6">6</xref>]. A hormonal trail is also retained in HAE. A Growth Hormone-like secreted by bronchial and gastric carcinomas is thought to be responsible for the proliferation of the periosteum [<xref ref-type="bibr" rid="scirp.109194-ref7">7</xref>]. Finally, it should be noted the probable role of the parasympathetic system in these vasodilations with regard to the improvement of symptoms after selective vagotomy [<xref ref-type="bibr" rid="scirp.109194-ref8">8</xref>].</p><p>We report the case of a 49-year-old female patient with secondary hypertrophic osteoarthropathy.</p></sec><sec id="s2"><title>2. Observation</title><p>Patient informed consent was obtained for publication of the case and associated images</p><p>A 49-year-old woman with a history of asthma and depression, active smoking, one pack a day for 20 years, seen in consultation for pain and swelling of the hands, elbows, knees, ankles, and feet evolving for about 5 months. On history, she reported a weight loss of about 8 kg, no fever, no cough, no family history of inflammatory rheumatism or cancer. She is not taking any medication except Pulmicort and Ventolin. The clinical examination noted swelling in the hands, ankles and feet and synovitis of the elbow and left knee. Bilateral digital clubbing was noted. On the respiratory system, the vesicular murmur was perfectly perceived in the two fields, without additional sound. The lymph node areas remained free.</p><p>The biological workup showed a biological inflammatory syndrome with an erythrocyte sedimentation rate (ESR) accelerated to 58 mm (normal value: 20 mm/h) at the 1<sup>st</sup> hour and a positive C reactive protein (CRP) at 102 mg/l (normal value: &lt;6 mg/l). The immunological and infectious results were negative.</p><p>The x-ray of the hands, feet, forearms and legs showed periosteal apposition at the shaft of the long bones (<xref ref-type="fig" rid="fig1">Figure 1</xref>) and the bone scan also showed hyper fixation at the long bone level. The chest x-ray noted a triangular opacity in the upper right lobe (<xref ref-type="fig" rid="fig2">Figure 2</xref>(a)).</p><p>Additional investigations, in particular the chest CT scan, showed a right supra-hilar tumour mass invading the right upper mediastinum associated with multiple supracimimetric lymphadenopathies especially in the right upper mediastinum (<xref ref-type="fig" rid="fig2">Figure 2</xref>(b)). The PET scan showed a large heterogeneous and</p><p>intensely hyper-metabolic right supra-hilar mass (<xref ref-type="fig" rid="fig2">Figure 2</xref>(c)). The bronchial biopsy showed a poorly differentiated lung carcinoma. Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and chemotherapy couple with radiotherapy was started.</p><p>After a 3-month follow-up, the joint damage disappeared as long as there was a worsening of the respiratory symptoms and the patient was hospitalized in intensive care or she died three weeks after admission.</p></sec><sec id="s3"><title>3. Discussion</title><p>HAO is a syndrome characterized by the association of digital clubbing, polyarthritis and periostitis affecting the long bones [<xref ref-type="bibr" rid="scirp.109194-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.109194-ref3">3</xref>].</p><p>The precise incidence and prevalence of HAO is unknown [<xref ref-type="bibr" rid="scirp.109194-ref9">9</xref>]. The age of onset has a bimodal distribution, with the initial peak occurring in the first year of life and the other during puberty.</p><p>Most affected are males; research has described both autosomal dominant and recessive inheritance.</p><p>HAO can be of primary genetic origin (autosomal dominant) called pachydermoperiostosis [<xref ref-type="bibr" rid="scirp.109194-ref10">10</xref>]. Much more often, it is a secondary manifestation due to a wide range of disease, most commonly paraneoplastic syndromes which are associated with lung cancer [<xref ref-type="bibr" rid="scirp.109194-ref11">11</xref>]. However, other non-neoplastic lung diseases have been mentioned, such as infections, inflammatory diseases (sarcoidosis), arteriovenous malformations, and extra-pulmonary diseases, such as cardiovascular disease, cirrhosis, and chronic inflammatory bowel disease [<xref ref-type="bibr" rid="scirp.109194-ref12">12</xref>]. Malignant lung tumours, whether primary or metastatic, are responsible for approximately 80% of secondary HAO cases, and most patients are diagnosed with adenocarcinoma as reported in our case [<xref ref-type="bibr" rid="scirp.109194-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.109194-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.109194-ref12">12</xref>]. There is no gender predominance, and the average age is 55 to 75 years [<xref ref-type="bibr" rid="scirp.109194-ref13">13</xref>]. However, in our case, the patient was 49-year-old.</p><p>The etiopathogenesis of secondary hypertrophic osteoarthropathy has been largely attributed to a neurogenic or vascular pathway triggered by circulating growth factors. The vascular pathway can be classified into two subtypes: 1) hypersecretion of vasoactive agents by the tumour itself or hypoxemia and 2) mechanical release of vasoactive agents into the systemic circulation due to 'an arteriovenous shunt in the pulmonary circulation [<xref ref-type="bibr" rid="scirp.109194-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.109194-ref14">14</xref>]. There is also evidence that circulating growth factors, such as platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) or prostaglandin E2 (PGE2), cause the triad (digital clubbing, polyarthritis and periostitis) [<xref ref-type="bibr" rid="scirp.109194-ref14">14</xref>], promoting angiogenesis, vasodilation, hyperplasia, interstitial oedema and collagen deposition in tissues [<xref ref-type="bibr" rid="scirp.109194-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.109194-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.109194-ref16">16</xref>].</p><p>The prognosis and treatment of secondary HAO are naturally linked to the primary aetiology [<xref ref-type="bibr" rid="scirp.109194-ref17">17</xref>]. Definitive treatment aims to remedy the underlying cause, including surgical resection, definitive chemotherapy or radiofrequency ablation for a primary malignancy of the lung [<xref ref-type="bibr" rid="scirp.109194-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.109194-ref18">18</xref>]. Symptomatic treatment (NSAIDs, octreotide, bisphosphonates, and specific growth factor inhibitors) is used in patients in whom the primary aetiology cannot be treated [<xref ref-type="bibr" rid="scirp.109194-ref19">19</xref>].</p></sec><sec id="s4"><title>4. Conclusion</title><p>The diagnosis of hypertrophic osteoarthropathy is based on clinical and radiographic evidence. It is considered that a paraneoplastic syndrome associated with lung cancer in 80% of cases. The prognosis and treatment of secondary hypertrophic osteoarthropathy are naturally linked to the primary aetiology.</p></sec><sec id="s5"><title>Conflicts of Interest</title><p>The authors declare that they have no conflicts of interest.</p></sec><sec id="s6"><title>Cite this paper</title><p>Cond&#233;, K., Guelngar, C.O., Mohamed, A., Kadidjatou, I., Daouya, D.G., Barry, M.C., Diallo, M.H., Diawara, K., Mamady, K., Moriba, T. and Ciss&#233;, F.A. (2021) Secondary Hypertrophic Osteoarthropathy or Pierre-Marie Syndrome Bamberger: Clinical Case and Literature Review. Open Journal of Rheumatology and Autoimmune Diseases, 11, 73-78. https://doi.org/10.4236/ojra.2021.112009</p></sec></body><back><ref-list><title>References</title><ref id="scirp.109194-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Yap, F.Y., Skalski, M.R., Patel, D.B., et al. (2017) Hypertrophic Osteoarthropathy: Clinical and Imaging Features. RadioGraphics, 37, 157-195. https://doi.org/10.1148/rg.2017160052</mixed-citation></ref><ref id="scirp.109194-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Mauricio, O., Francis, L., Athar, U., et al. (2009) Hypertrophic Osteoarthropathy Masquerading as Lower Extremity Cellulitis and Response to Bisphosphonates. Journal of Thoracic Oncology, 4, 260-262. https://doi.org/10.1097/JTO.0b013e3181952915</mixed-citation></ref><ref id="scirp.109194-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ribigan, A.C., Bajenaru, O.L., Antochi, F.A. and Bajenaru, O.A. (2019) Nociceptive Pain Unmasking a Serious Pathology-Paraneoplastic Hypertrophic Osteoarthropathy: A Case Report. Medicine (Baltimore), 98, e15900. https://doi.org/10.1097/MD.0000000000015900</mixed-citation></ref><ref id="scirp.109194-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Yao, Q., Altman, R.D. and Brahn, E. (2009) Periostitis and Hypertrophic Pulmonary Osteoarthropathy: Report of 2 Cases and Review of the Literature. Seminars in Arthritis and Rheumatism, 38, 458-466. https://doi.org/10.1016/j.semarthrit.2008.07.001</mixed-citation></ref><ref id="scirp.109194-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Nobuhiro, K., Naoki, W., Nobuyuki, K., et al. (2014) Paraneoplastic Syndromes Associated with Lung Cancer. World Journal of Clinical Oncology, 5, 197-223.https://doi.org/10.5306/wjco.v5.i3.197</mixed-citation></ref><ref id="scirp.109194-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rouers, A., Radermecker, M.A., Duysinx, B., Kaschten, B. and Limet, R. (2006) LE CAS CLINIQUE DU MOIS Le syndrome de Pierre-Marie Bamberger. Revue Médicale de Liège, 61, 142-144.</mixed-citation></ref><ref id="scirp.109194-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Nakonechnaya, A.O. and Shewchuk, B.M. (2015) Growth Hormone Enhances LNCaP Prostate Cancer Cell Motility. Endocrine Research, 40, 97-105. https://doi.org/10.3109/07435800.2014.966383</mixed-citation></ref><ref id="scirp.109194-ref8"><label>8</label><mixed-citation publication-type="book" xlink:type="simple">Goldstein, D.S. (2013) Differential Responses of Components of the Autonomic Nervous System. In: Buijs, R.M. and Swaab, D.F., Eds., Handbook of Clinical Neurology, Volume 117, Elsevier, 13-22. http://www.sciencedirect.com/science/article/pii/B978044453491000002X https://doi.org/10.1016/B978-0-444-53491-0.00002-X</mixed-citation></ref><ref id="scirp.109194-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Z., Zhang, C. and Zhang, Z. (2013) Primary Hypertrophic Osteoarthropathy: An Update. Frontiers of Medicine, 7, 60-64. https://doi.org/10.1007/s11684-013-0246-6</mixed-citation></ref><ref id="scirp.109194-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Tan, I., Lomasney, L., Stacy, G.S., Lazarus, M. and Mar, W.A. (2019) Spectrum of Voriconazole-Induced Periostitis with Review of the Differential Diagnosis. American Journal of Roentgenology, 212, 157-165. https://doi.org/10.2214/AJR.18.19991</mixed-citation></ref><ref id="scirp.109194-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Pineda, C. and Martínez-Lavín, M. (2013) Hypertrophic Osteoarthropathy: What a Rheumatologist Should Know about This Uncommon Condition. Rheumatic Disease Clinics North America, 39, 383-400. https://doi.org/10.1016/j.rdc.2013.02.008</mixed-citation></ref><ref id="scirp.109194-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Meyer, H.J., Leifels, L., Bach, A.G., et al. (2017) Secondary Hypertrophic Osteoarthropathy Caused by Non-Pleural or Pulmonary Tumors. Medicine (Baltimore), 96, e7985. https://doi.org/10.1097/MD.0000000000007985</mixed-citation></ref><ref id="scirp.109194-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ito, T., Goto, K., Yoh, K., Niho, S., Ohmatsu, H., Kubota, K., Nagai, K., Miyazaki, E., Kumamoto, T. and Nishiwaki, Y. (2010) Hypertrophic Pulmonary Osteoarthropathy as a Paraneoplastic Manifestation of Lung Cancer. Journal of Thoracic Oncology, 5, 976-980. https://doi.org/10.1097/JTO.0b013e3181dc1f3c</mixed-citation></ref><ref id="scirp.109194-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Davis, M.C. and Sherry, V. (2011) Hypertrophic Osteoarthropathy as a Clinical Manifestation of Lung Cancer. Clinical Journal of Oncology Nursing, 15, 561-563. https://doi.org/10.1188/11.CJON.561-563</mixed-citation></ref><ref id="scirp.109194-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Chakraborty, R.K. and Sharma, S. (2018) Secondary Hypertrophic Osteoarthropathy. In: StatPearls, Treasure Island, FL. https://www.ncbi.nlm.nih.gov/books/NBK513342/</mixed-citation></ref><ref id="scirp.109194-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kozak, K.R., Milne, G.L., Bentzen, S.M. and Yock, T.I. (2012) Elevation of Prostaglandin E2 in Lung Cancer Patients with Digital Clubbing. Journal of Thoracic Oncology, 7, 1877-1878. https://doi.org/10.1097/JTO.0b013e3181fc76a9</mixed-citation></ref><ref id="scirp.109194-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Pourmorteza, M., Baumrucker, S.J., Al-Sheyyab, A. and Da Silva, M.A. (2015) Hypertrophic Pulmonary Osteoarthropathy: A Rare but Treatable Condition in Palliative Medicine. Journal of Pain and Symptom Management, 50, 263-267. https://doi.org/10.1016/j.jpainsymman.2015.02.005</mixed-citation></ref><ref id="scirp.109194-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Fang, Y.H., Hsu, C.C., Hsieh, M.J., Hung, M.S., Tsai, Y.H. and Lin, Y.C. (2017) Impact of Hypertrophic Pulmonary Osteoarthropathy on Patients with Lung Cancer. OncoTargets and Therapy, 10, 5173-5177. https://doi.org/10.2147/OTT.S139558</mixed-citation></ref><ref id="scirp.109194-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Birch, E., Jenkins, D. and Noble, S. (2011) Treatment of Painful Hypertrophic Osteoarthropathy Associated with Non-Small Cell Lung Cancer with Octreotide: A Case Report and Review of the Literature. BMJ Supportive &amp; Palliative Care, 1, 189-192. https://doi.org/10.1136/bmjspcare-2011-000052</mixed-citation></ref></ref-list></back></article>